Topical GHK-Cu has a favorable safety record in cosmetic use. Systemic (injectable) safety in humans is not well-established. No controlled injectable safety studies have been published. The peptide is endogenous to the human body, which provides some biological reassurance, but exogenous supplementation at non-physiological doses has not been rigorously evaluated. Discuss with a physician.

Does GHK-Cu really reverse skin aging?

Topical studies show measurable improvements in skin thickness and elasticity. 'Reversing aging' overstates the evidence. It may slow visible signs of skin aging with consistent topical use, but controlled trial data is limited. It is not a substitute for established dermatological treatments.

What is the difference between topical and injectable GHK-Cu?

Topical GHK-Cu has decades of cosmetic use data supporting skin improvement. Injectable GHK-Cu has almost no human safety or efficacy data. They are not interchangeable in terms of evidence support. Topical use has a known safety profile. Injectable use is investigational.

Is GHK-Cu FDA-approved?

No. GHK-Cu is not FDA-approved for any therapeutic indication. It is used as a cosmetic ingredient (which does not require FDA drug approval). Injectable forms are investigational and were placed on the FDA's Category 2 restricted list. Expected to return to Category 1 following the February 2026 HHS announcement.

How does GHK-Cu compare to retinol?

Retinol (vitamin A) has decades of controlled clinical trial data for skin aging and is considered the gold standard for topical anti-aging. GHK-Cu has a different mechanism (copper delivery + gene expression modulation) with less robust clinical evidence. Retinol is the more evidence-backed option. GHK-Cu may complement retinol but should not be considered a replacement.

What does the research show about: Naturally occurring tripeptide (Gly-His-Lys) with copper binding, found in human?

Naturally occurring tripeptide (Gly-His-Lys) with copper binding, found in human plasma, saliva, and urine, with levels declining significantly with age. The endogenous origin and age-related decline provide a compelling biological narrative, but declining levels do not automatically mean supplementation is beneficial

What does the research show about: Gene expression studies suggest GHK-Cu modulates 4,000+ genes, an unusually broa?

Gene expression studies suggest GHK-Cu modulates 4,000+ genes, an unusually broad transcriptomic footprint for a tripeptide. This breadth of gene modulation is the basis for claims spanning wound healing, anti-aging, anti-inflammation, and anti-cancer activity. However, gene expression changes do not equal clinical outcomes

What tissue repair evidence exists for this compound?

In vitro evidence for collagen synthesis, wound healing, and anti-inflammatory activity is consistent across multiple independent labs. The mechanistic data is the strongest component of the GHK-Cu evidence base, but in vitro consistency has not yet translated to controlled human clinical trials

Have any randomized controlled human trials been completed?

Human data is almost entirely limited to topical cosmetic applications. No controlled systemic trials published. The gap between in vitro promise and clinical validation is the defining limitation. Topical skin improvement in cosmetic studies is the only human outcome with any meaningful data

reviewed april 2026|next review october 2026|88 physicians psi has verified|186 published studies

GHK-Cu

Glycyl-histidyl-lysine copper complex (GHK-Cu) is a naturally occurring (the body's own) copper-binding tripeptide that modulates the expression of over 4,000 human genes in transcriptomic studies, with decades of topical cosmetic use and zero controlled human trials for injectable administration.

Evidence landscape: 186 published studies

186 published items. 4 human studies and 166 animal studies. Striking mechanistic profile with a wide gap between laboratory data and clinical validation.

4 Human
166 Animal
16 Reviews

Not FDA-approved as a drug. Widely used in cosmetic skincare products. Injectable form was placed on the FDA Category 2 restricted list and is expected to return to Category 1 following the February 2026 HHS announcement.

Topical human studies show measurable skin improvements (thickness, elasticity). Over 4,000 genes modulated in transcriptomic studies. Zero controlled human trials for injectable use.

The widest gap between mechanistic promise and clinical validation of any compound on this platform. Naturally occurring in human plasma with levels declining approximately 60% between the 20s and 60s.

PSI Assessment

The gap between mechanistic promise and clinical validation is wider for GHK-Cu than for almost any other compound on this platform. This copper-binding tripeptide modulates the expression of over 4,000 human genes in transcriptomic studies, a breadth of gene regulation that is unmatched among peptides. Topical skincare studies show measurable improvements in skin thickness and elasticity. But for injectable use, the most common route in functional medicine, controlled human trial data does not exist.

Over 4,000 genes modulated in transcriptomic studies. Decades of topical cosmetic use. Zero controlled human trials for injectable use.

The mechanism centers on copper delivery and broad gene expression modulation. GHK (glycyl-histidyl-lysine) binds copper(II) with high affinity, delivering it to tissue sites where copper-dependent enzymes drive tissue repair: lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defense, cytochrome c oxidase for cellular energy. The peptide occurs naturally in human plasma, with levels declining approximately 60% between the 20s and 60s.

What the evidence supports

GHK-Cu stimulates collagen synthesis, accelerates wound healing, and reduces inflammation in cell culture and animal models. Topical human studies show measurable skin improvements in thickness and elasticity. The copper-binding mechanism and gene expression profile (over 4,000 genes modulated) are well-characterized across multiple independent research groups.

What is not yet established

Whether injectable GHK-Cu produces systemic anti-aging effects in humans. No controlled human trials exist for injectable use. Whether the gene expression changes observed in laboratory studies translate to meaningful clinical outcomes. Long-term safety of regular injectable administration.

Research Evidence

The findings below cover the gene expression profile, topical evidence, and the gap between mechanistic data and clinical validation for injectable use.

Evidence by condition

Evidence dimensions across GHK-Cu indications. Topical skin applications have cosmetic study support. All injectable systemic claims lack controlled human data.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Skin Aging/Rejuvenation
Wound Healing
Anti-Inflammatory
Tissue Remodeling
Hair Growth

Transcriptomic studies show GHK-Cu modulates over 4,000 genes, an unusually broad regulatory footprint for a tripeptide. Affected genes span tissue repair, inflammation, antioxidant defense, and extracellular matrix remodeling.

Gene expression changes are not clinical outcomes. This breadth of modulation is the basis for claims spanning wound healing, anti-aging, and anti-inflammation, but changing gene expression in a laboratory does not confirm therapeutic effects in living systems.

Topical GHK-Cu creams show measurable improvements in skin thickness, elasticity, and fine line reduction in cosmetic studies. The copper-delivery mechanism supports collagen synthesis and antioxidant defense in skin.

Cosmetic studies typically lack placebo controls and rigorous methodology. Results apply to topical application only. The leap from topical skin effects to systemic injectable benefits is not supported by evidence.

No controlled human trials exist for injectable GHK-Cu. The most common route used in functional medicine (subcutaneous injection) has no published safety or efficacy data from controlled studies.

The gap between laboratory promise and clinical validation is the defining characteristic of GHK-Cu research. Decades of topical use do not validate injectable systemic claims.

4 Human|166 Animal|16 Reviews

View all 186 indexed studies

How GHK-Cu Works

GHK (glycyl-L-histidyl-L-lysine) binds copper(II) ions with high affinity, forming a stable 1:1 complex. The peptide modulates TGF-B (transforming growth factor-beta) superfamily signaling, upregulates collagen I, collagen III, decorin, and integrins, and downregulates metalloproteinases (MMPs) that degrade extracellular matrix. The copper delivery function supports lysyl oxidase, superoxide dismutase, and cytochrome c oxidase activity.

GHK-Cu acts like a master reset signal for aging cells. It appears to turn on genes involved in repair and turn off genes associated with inflammation and disease. Your body naturally produces it, but levels fall by about 60% between your 20s and 60s.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

GHK-Cu works through multiple pathways centered on copper delivery and gene regulation. The copper ion is essential for many enzymes involved in tissue repair, including lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (cellular energy). By delivering copper to tissue sites, GHK-Cu supports these enzymatic processes while also directly modulating gene expression related to tissue remodeling, inflammation reduction, and stem cell recruitment.

What is GHK-Cu being studied for?

Researchers are studying GHK-Cu across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for GHK-Cu overall. This means a compound can have human studies for one condition but only animal data for another.

Skin Aging/Rejuvenation

·Animal Studies

Topical studies show GHK-Cu improves skin thickness, elasticity, and reduces fine lines. It stimulates collagen and glycosaminoglycan synthesis in skin fibroblasts.

Limitations: Cosmetic studies typically lack placebo controls and rigorous methodology. Results apply to topical application only. Systemic anti-aging effects are speculative.

Wound Healing

·Animal Studies

Animal and laboratory studies show GHK-Cu accelerates wound closure and reduces scarring. The peptide promotes cell migration to injury sites and stimulates new blood vessel formation.

Limitations: Most evidence is from laboratory or animal studies. Human wound-healing data is limited to topical applications. No systemic (injectable) wound-healing trials in humans.

Anti-Inflammatory

·Animal Studies

GHK-Cu suppresses inflammatory cytokines and modulates NF-kB signaling in cell and animal studies. The anti-inflammatory effect is well-documented mechanistically.

Limitations: No human anti-inflammatory studies. Laboratory anti-inflammatory effects do not confirm systemic anti-inflammatory utility in humans.

Tissue Remodeling

·Animal Studies

GHK-Cu influences the expression of genes involved in extracellular matrix remodeling, including metalloproteinases and collagen types. This broad gene-regulatory activity is unique among peptides.

Limitations: Gene expression changes are not clinical outcomes. Published human data has not confirmed that these transcriptomic shifts produce measurable tissue remodeling in living systems.

Hair Growth

·Preclinical

Animal study data suggests GHK-Cu may stimulate hair follicle growth by enlarging follicle size. Human data is limited to small observational reports.

Limitations: Essentially no controlled human data for hair growth. Claims are based on cell studies and anecdotal reports.

Safety and Regulatory Status

FDA Status: Not FDA-approved as a drug. Widely used in over-the-counter cosmetic skincare products. Injectable form was placed on the FDA's Category 2 list (a designation that temporarily prevented licensed pharmacies from preparing this compound), meaning it is expected to return to legal pharmacy preparation status following the February 2026 HHS announcement.

Availability: Topical GHK-Cu products are widely available without prescription. Injectable form is expected to return to legal pharmacy preparation status following the February 2026 HHS announcement, meaning a licensed pharmacist would again be able to prepare it from ingredients for an individual patient.

Class context: Naturally occurring (the body's own) copper-binding tripeptide. Found in human plasma with levels declining with age. BPC-157 and TB-500 are tissue repair comparators with different mechanisms.

Favorable safety profile in topical use with decades of cosmetic application history. Injectable safety data in humans is limited. As a naturally occurring peptide that declines with age, the theoretical safety profile is favorable, but theoretical safety is not established safety.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a GHK-Cu discussion.

Comparison and Related Research

GHK-Cu is most often compared with other tissue repair and longevity peptides. The comparisons below outline how each differs in mechanism, evidence depth, and administration route.

Head-to-head comparisons

Full research comparisons covering GHK-Cu and another peptide side by side.

GHK-Cu vs BPC-157

Three-way comparison of BPC-157, TB-500, and GHK-Cu for tissue repair and regeneration research. Mechanisms, evidence levels, study types, and key limitations analyzed.

View full comparison

GHK-Cu vs BPC-157

BPC-157 targets deep tissue repair. GHK-Cu targets skin and collagen. Evidence-graded comparison of mechanisms, study data, and which peptide fits which goal.

View full comparison

GHK-Cu vs Epitalon

Both target aging through different mechanisms. Epitalon works on telomeres. GHK-Cu works on collagen and skin. Evidence-graded comparison of two Animal Studies anti-aging peptides.

View full comparison

GHK-Cu vs TB-500

TB-500 targets deep tissue through actin regulation. GHK-Cu targets skin through collagen. Evidence-graded comparison of two healing peptides.

View full comparison

GHK-Cu vs Retinol (Vitamin A)

Retinol has decades of clinical evidence. GHK-Cu has interesting collagen mechanisms but less validation. Honest comparison for skincare research.

View full comparison

Related compounds

BPC-157 TB-500 Epitalon GHK

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Review examining how the copper-binding tripeptide GHK-Cu may help protect against age-related tissue decline. The paper synthesized evidence on antioxidant activity, wound repair support, and potential neuroprotective effects across multiple preclinical models.Pickart L et al., 2012 in Oxid Med Cell Longev. View on PubMed
2.Comprehensive analysis of gene expression data showing GHK-Cu influences over 4,000 human genes. The paper identified gene activity changes relevant to tissue repair, anti-inflammatory signaling, and antioxidant defense - broadening the understanding of how this peptide interacts with cellular processes.Pickart L & Margolina A, 2018 in Int J Mol Sci. View on PubMed
3.Laboratory study showing that GHK-Cu increased expression of key proteins involved in skin cell adhesion and wound healing. The results suggested a mechanism by which this peptide may support skin repair at the cellular level.Kang YA et al., 2009 in Arch Dermatol Res. View on PubMed
4.Review of GHK-Cu's role in skin biology, including evidence that it modulates inflammation, promotes collagen synthesis, and influences gene expression related to tissue remodeling. The paper described the Connectivity Map analysis that linked GHK to suppression of genes associated with aggressive cancer phenotypes.Pickart L et al., 2015 in Biomed Res Int. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.